Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00091182 |
Recruitment Status :
Completed
First Posted : September 9, 2004
Last Update Posted : June 5, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Childhood Central Nervous System Germ Cell Tumor Childhood Extragonadal Germ Cell Tumor Childhood Hepatoblastoma Childhood Hepatocellular Carcinoma Childhood High-grade Cerebral Astrocytoma Childhood Low-grade Cerebral Astrocytoma Childhood Malignant Ovarian Germ Cell Tumor Childhood Malignant Testicular Germ Cell Tumor Childhood Teratoma Recurrent Adrenocortical Carcinoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Liver Cancer Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Childhood Visual Pathway and Hypothalamic Glioma Recurrent Colon Cancer Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Nasopharyngeal Cancer Recurrent Neuroblastoma Recurrent Osteosarcoma Recurrent Rectal Cancer Recurrent Renal Cell Cancer | Drug: oxaliplatin | Phase 2 |
OBJECTIVES:
I. Determine the response rate in children with recurrent or refractory solid tumors treated with oxaliplatin.
II. Determine the cumulative toxicity of this drug in these patients. III. Determine the pharmacokinetic profile of this drug in these patients. IV. Determine time to progression and overall survival of patients treated with this drug.
V. Correlate the extent of oxaliplatin exposure with response in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to disease type.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 180 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors |
Study Start Date : | October 2004 |
Actual Primary Completion Date : | February 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm I
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: oxaliplatin
Given IV
Other Names:
|
- Response rate [ Time Frame: Up to 3 years ]Response rate and confidence intervals will be constructed according to the method of Chang and O'Brien.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Histologically confirmed* solid tumor, including any of the following:
- Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)
- Osteosarcoma
- Rhabdomyosarcoma
- Neuroblastoma
- High-grade astrocytoma
- Low-grade astrocytoma
- Glioblastoma multiforme
- Ependymoma
- Hepatoblastoma
- Germ cell tumors of any site
-
Rare tumors of interest, including any of the following:
- Soft tissue sarcoma
- Hepatocellular carcinoma
- Childhood/adolescent colorectal carcinoma
- Childhood/adolescent renal cell carcinoma
- Childhood/adolescent adrenocortical carcinoma
- Childhood/adolescent nasopharyngeal carcinoma
- Recurrent disease OR refractory to conventional therapy
- Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography
- Performance status - Karnofsky 50-100% (for patients over age 10)
- Performance status - Lansky 50-100% (for patients age 10 and under)
- At least 8 weeks
- Absolute neutrophil count ≥ 1,000/mm^3*
- Platelet count ≥ 75,000/mm^3* (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)
- Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or extensive prior radiotherapy allowed provided the above hematological criteria are met
- Bilirubin ≤ 3 mg/dL
-
Creatinine based on age as follows:
- ≤ .8 mg/dL (for patients age 5 and under)
- ≤ 1.0 mg/dL (for patients age 6 to 10)
- ≤ 1.2 mg/dL (for patients age 11 to 15)
- ≤1.5 mg/dL (for patients age 16 to 21)
- Creatinine clearance or radioisotope glomerular filtration rate > 20 mL/min
- No uncontrolled seizure disorder
- No uncontrolled infection
- CNS toxicity ≤ grade 2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Recovered from prior immunotherapy
- At least 7 days since prior anticancer biologic therapy
- More than 1 week since prior growth factors
-
At least 6 months since prior allogeneic stem cell transplantation
- No evidence of active graft-vs-host disease
- No concurrent immunomodulating agents
- Recovered from prior chemotherapy
- No prior oxaliplatin
- Prior carboplatin or cisplatin allowed
- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
- No other concurrent anticancer chemotherapy
- Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable or decreasing dose for ≥ 1 week before study entry
- Recovered from prior radiotherapy
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 months since prior craniospinal radiotherapy
- At least 6 months since prior radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial radiotherapy to the bone marrow
- Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable lesion is not irradiated
- No other concurrent investigational agents
- No other concurrent anticancer agents

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00091182
United States, California | |
Children's Oncology Group | |
Arcadia, California, United States, 91006-3776 |
Principal Investigator: | Orren Beaty | Children's Oncology Group |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00091182 |
Other Study ID Numbers: |
NCI-2012-01815 ADVL0421 COG-ADVL0421 CDR0000384560 U10CA098543 ( U.S. NIH Grant/Contract ) |
First Posted: | September 9, 2004 Key Record Dates |
Last Update Posted: | June 5, 2013 |
Last Verified: | June 2013 |
Carcinoma Neoplasms Sarcoma Glioma Neuroblastoma Neoplasms, Germ Cell and Embryonal Astrocytoma Carcinoma, Renal Cell Osteosarcoma Rhabdomyosarcoma Ependymoma Sarcoma, Ewing Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Teratoma |
Nasopharyngeal Neoplasms Nasopharyngeal Carcinoma Testicular Neoplasms Neuroectodermal Tumors, Primitive, Peripheral Adrenocortical Carcinoma Hepatoblastoma Glioblastoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Adenocarcinoma Neoplasms by Site Neoplasms, Neuroepithelial Neoplasms, Nerve Tissue Kidney Neoplasms |